Stereotaxis (STXS) AI Stock Analysis

• Market Cap: $251.36M
• Dividend Yield: N/A
• Average Volume (3M): 469.42K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.78
• Revenue Growth: 33.94%
• EPS Growth: -6.91%
• Country: US
• Employees: 139
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.05
• Shares Outstanding: 91,071,480
• 10 Day Avg. Volume: 331,358
• 30 Day Avg. Volume: 469,416
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.76
• Enterprise Value/Revenue: 6.93
• Enterprise Value/Gross Profit: 12.97
• Enterprise Value/Ebitda: -7.74
• 1Y Price Target: $4.50
• Price Target Upside: 60.14% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 66 Neutral
• Price Target: $3.00 ▲(6.76% Upside)

Stereotaxis' stock score is driven by strong technical momentum and positive earnings call highlights, including significant revenue growth and strategic product launches. However, ongoing profitability challenges and a negative valuation score due to a negative P/E ratio and lack of dividend yield temper the overall score.

Positive Factors

Revenue Growth

The significant revenue growth indicates strong market demand and successful product adoption, enhancing long-term business prospects.

Product Innovation

FDA clearance for new products like MAGiC Sweep enhances Stereotaxis' competitive edge and expands its market reach, supporting sustained growth.

Strategic Financing

The strategic financing strengthens the balance sheet, providing capital for product commercialization and R&D, crucial for long-term innovation.

Negative Factors

Profitability Challenges

Continued operating losses highlight ongoing profitability challenges, which could impede financial sustainability if not addressed.

Negative Cash Flow

Negative cash flow indicates difficulties in converting revenue into cash, potentially affecting liquidity and operational flexibility.

Administrative Challenges

Administrative challenges in Europe could delay product adoption and revenue growth, hindering international expansion efforts.

Stereotaxis Business Overview & Revenue Model

Company Description

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.

How the Company Makes Money

Stereotaxis generates revenue primarily through the sale of its robotic systems, disposable catheters, and software solutions. The company earns money from the initial sale of its Niobe® systems to hospitals and medical institutions, which is often accompanied by service agreements and maintenance contracts that provide ongoing revenue. Additionally, Stereotaxis benefits from recurring revenue through the sale of disposable catheters used in procedures performed with its robotic systems. Partnerships with hospitals and medical centers, as well as collaborations with other medical technology firms, also contribute to its earnings by expanding its customer base and enhancing its product offerings.

Stereotaxis Financial Statement Overview

Summary

Stereotaxis shows consistent revenue but struggles with profitability due to high operational costs, leading to negative net income. The balance sheet indicates balanced leverage but limited equity, while cash flow constraints highlight the need for improved cash management.

Income Statement

Stereotaxis has shown marginal revenue growth over the years but faces challenges in profitability. The gross profit margin remains robust at around 54.2% for 2024, but the company continues to operate at a net loss, with a net profit margin of -94.2% in 2024. This indicates high operational costs relative to revenue, leading to negative EBIT and EBITDA margins, which suggest a need for cost management and strategic improvements.

Balance Sheet

The debt-to-equity ratio for 2024 stands at approximately 0.99, showing a balanced leverage profile. However, the equity ratio is relatively low at 13.0%, indicating limited asset backing by equity. The company’s return on equity is negative due to sustained losses, highlighting potential financial stability concerns.

Cash Flow

Free cash flow has seen a slight improvement but remains negative, reflecting cash outflow challenges. The operating cash flow to net income ratio is unfavorable due to negative cash flows, indicating issues in converting revenue into cash. The free cash flow to net income ratio also highlights cash generation difficulties, requiring strategic cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	27.51M	26.92M	26.77M	28.15M	35.02M	26.63M
Gross Profit	14.69M	14.59M	14.86M	18.47M	23.23M	18.97M
EBITDA	-24.62M	-23.77M	-21.24M	-18.35M	-12.78M	-6.59M
Net Income	-25.36M	-24.05M	-20.71M	-18.29M	-10.72M	-6.65M
Balance Sheet
Total Assets	45.70M	46.72M	41.91M	53.41M	60.98M	55.46M
Cash, Cash Equivalents and Short-Term Investments	10.60M	12.22M	19.82M	28.43M	38.74M	43.94M
Total Debt	5.87M	6.01M	5.49M	5.86M	6.11M	4.45M
Total Liabilities	37.53M	35.29M	19.99M	21.48M	21.56M	15.23M
Stockholders Equity	8.18M	11.43M	21.92M	31.93M	39.42M	40.23M
Cash Flow
Free Cash Flow	-7.96M	-8.53M	-9.51M	-10.79M	-4.34M	-3.58M
Operating Cash Flow	-7.93M	-8.50M	-9.14M	-8.41M	-2.95M	-3.51M
Investing Cash Flow	74.00K	74.00K	19.77M	-22.09M	-1.40M	-70.90K
Financing Cash Flow	299.00K	297.00K	81.00K	220.00K	547.41K	17.34M

Stereotaxis Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.81
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STXS, the sentiment is Neutral. The current price of 2.81 is below the 20-day moving average (MA) of 2.82, above the 50-day MA of 2.58, and above the 200-day MA of 2.23, indicating a neutral trend. The MACD of 0.06 indicates Positive momentum. The RSI at 53.50 is Neutral, neither overbought nor oversold. The STOCH value of 31.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for STXS.

Stereotaxis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MMSI	79 Outperform	4.95B	42.45	8.01%	―	10.14%	0.04%
ATR	72 Outperform	8.86B	23.20	14.50%	1.34%	1.51%	21.70%
HOLX	69 Neutral	14.75B	27.52	11.50%	―	1.28%	-17.73%
STXS	66 Neutral	$251.36M	―	-198.62%	―	33.94%	-6.91%
ATRC	61 Neutral	1.81B	-47.37	-7.83%	―	16.28%	10.63%
STAA	56 Neutral	1.35B	-14.10	-28.31%	―	-32.59%	-667.81%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Stereotaxis Corporate Events

Stereotaxis Enters $50M Sales Agreement with Roth Capital

On August 29, 2025, Stereotaxis, Inc. entered into a Sales Agreement with Roth Capital Partners, LLC to sell up to $50 million in common stock. The proceeds are intended for working capital, research and development, and accelerating the commercialization of their innovation pipeline. This agreement allows Stereotaxis to offer shares through Roth Capital as sales agent or principal, with sales made as at-the-market offerings or through privately negotiated transactions. The arrangement provides flexibility in raising capital based on market conditions and the company’s needs, potentially impacting its operational capabilities and market positioning.

Stereotaxis Announces $12.5M Stock Offering

On July 17, 2025, Stereotaxis announced a $12.5 million registered direct offering of common stock, priced at $2.00 per share, led by a strategic industry partner and select institutional investors. The company plans to use the proceeds to accelerate product commercialization, research and development, and other corporate purposes. The initial closing is expected on July 18, 2025, with proceeds of $8.5 million, and a second closing on November 25, 2025, for $4.0 million. This funding is expected to strengthen Stereotaxis’ balance sheet and support its innovation strategy.